.Pharmacolibrary.Drugs.ATC.J.J01AA13

Information

Eravacycline is a synthetic fluorocycline antibiotic in the tetracycline class, primarily used for the treatment of complicated intra-abdominal infections and designed to overcome common tetracycline resistance mechanisms. It is approved by the FDA and EMA for clinical use.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects (both sexes) following intravenous infusion.

References

1. Ji, X-w, et al., & Zhu, X (2025). Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD. Antimicrobial agents and chemotherapy 69(3) e0106524–None. DOI:10.1128/aac.01065-24 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39878492

2. Zhanel, GG, et al., & Karlowsky, JA (2016). Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent. Drugs 76(5) 567–588. DOI:10.1007/s40265-016-0545-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26863149

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)